SemBioSys - Diabetes

By: Sembiosys  09-12-2011
Keywords: Insulin, Genetically Engineered

The Problem

Our Solution

To answer this need, SemBioSys is producing human insulin from genetically engineered safflower. We believe our plant-made insulin will offer dramatic reductions in capital and operating costs and provide an accessible source of insulin to meet this exploding demand. In fact, SemBioSys could meet this increased demand with just three commercial farms.

What We Have Accomplished

We have filed an Investigational New Drug (IND) application with the FDA and have submitted a Clinical Trial Application (CTA) to the appropriate European authorities. Discussions with the US Food and Drug Administration (FDA) have confirmed that safflower-produced insulin is eligible to follow a shortened drug approval process.

Clinical Trials

In December 2008, we initiated our Phase I/II clinical trial of safflower-produced insulin, now referred to as SBS-1000, in the UK. The trial demonstrated that SBS-    1000 was bioequivalent to a recombinant human insulin with the expected safety profile. Highlights from the analysis were:

  • SBS-1000 was bioequivalent to Eli Lilly's Humulin® R, a widely-used human insulin in North America
  • SBS-1000 in humans showed pharmacokinetics and pharmacodynamics indistinguishable from Eli Lilly's Humulin® R
  • SBS-1000 was well tolerated at pharmacologically active dosages.

What We Are Working On

In addition to traditional insulin, we are working on insulin analogues that provide faster-acting or slow-release options for improved disease control.

We are seeking well-positioned manufacturing and commercialization partners to co-develop plant-derived insulin across the developed and developing world.

Keywords: Genetically Engineered, Insulin

Contact Sembiosys

Email - none provided

Print this page

Other products and services from Sembiosys


SemBioSys - In Development

We have also developed an extraction process that we believe will allow for the production of chymosin in plants at significantly lower costs than current production systems. We have chosen to work on products for which the inherent benefits of our technology, including scalability and economics, enable them to be commercially viable.


SemBioSys - Personal Care

SemBioSys has developed an all-natural process to extract oilbodies from safflower seeds resulting in a base emulsion with superior hydration, skin conditioning and moisturization properties compared to traditional ingredients such as petrolatum or chemical and animal byproducts. Beyond the benefits as a personal care product ingredient, oilbodies hold the potential to act as a carrier and delivery system for pharmaceutical products.


SemBioSys - Technology

Our technology is built on two basic capabilities: the use of genetic engineering to attach high-value proteins to (the structures used by seeds to store oil); and extraction of oilbodies from seeds in a cost-effective manner. For the production of high-value proteins, we believe that our plant technology is unique among transgenic systems as it addresses both production and purification challenges.


SemBioSys - Heart Attack and Stroke

Cardiovascular diseases, including heart attack and stroke, are the leading causes of mortality in developed nations and by 2010, are projected to become the leading cause of mortality worldwide. Apo AI is the major protein associated with high density lipoprotein, or "good cholesterol", whose function is to remove excess cholesterol from arteries.


SemBioSys - Overview

The same advantages that drive our pharmaceutical opportunities also apply to our non-pharmaceutical products, which include topical ingredients that are delivering innovation and value for personal care producers, nutritional oils for use in a variety of consumer goods, and applications for agricultural biotechnology.